Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CLK1 | P49759 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | MELK | Q14680 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7980560 | 0.91 | CYP1A2 (0.59) | CYP1A2CYP2A6MAPTCLK1DYRK1A | |
| SCHEMBL18266963 | 0.81 | CYP1A2 (0.67) | CYP1A2CYP2A6ABL1UHRF1 | |
| SCHEMBL12731941 | 0.78 | CYP1A2 (0.44) | CYP1A2CYP2A6MAPTCLK1DYRK1A | |
| SCHEMBL17532791 | 0.78 | MAPK10 (0.45) | CYP1A2CYP2A6CLK1DYRK1AWNT3A | |
| SCHEMBL17532782 | 0.76 | CYP1A2 (0.42) | CYP1A2CYP2A6CLK1DYRK1AIMPDH2 | |
| SCHEMBL17532787 | 0.76 | DYRK1A (0.46) | CYP1A2CYP2A6CLK1DYRK1AABL1 | |
| SCHEMBL18899958 | 0.76 | ABL1 (0.59) | CYP1A2CYP2A6DYRK1AABL1 | |
| SCHEMBL17090673 | 0.76 | CYP1A2 (0.61) | CYP1A2CYP2A6ABL1UHRF1 | |
| SCHEMBL152013 | 0.75 | CYP19A1 (0.45) | CYP1A2CYP2A6MAPTCLK1DYRK1A | |
| SCHEMBL8292355 | 0.75 | CLK1 (0.46) | CLK1DYRK1ACSNK1DCSNK1EPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-11825740-B2 | Amine compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| US-11744146-B2 | Amine-based compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-08-29 | — | — | US | disclosed |
| US-11696499-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11696499-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11690289-B2 | Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-27 | — | — | US | disclosed |
| WO-2023110138-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11678498-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-13 | — | — | US | disclosed |
| US-20160260905-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-09-08 | — | — | US | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-8962627-B2 | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors | PRESTWICK CHEMICAL, INC. (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2493871-B1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2014-09-03 | — | — | EP | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | GPX1, LAGE3, NFE2L2 | CYP1A2 268/4885CYP2A6 814/4885MAPT 2006/4885 |
| US-11690289-B2 | Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same | LEF1, PPOX, LIMK1 | CYP1A2 77/4885CYP2A6 1011/4885MAPT 2035/4885 |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | CYP1A2 698/4885CYP2A6 1072/4885MAPT 1423/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | CYP1A2 3/4885CYP2A6 337/4885MAPT 1675/4885 |
| US-11744146-B2 | Amine-based compound and organic light-emitting device including the same | AOC2, AOC1, EML4 | CYP1A2 456/4885CYP2A6 2759/4885MAPT 365/4885 |
| US-11825740-B2 | Amine compound and organic light-emitting device including the same | AOC2, AOC1, AOC3 | CYP1A2 126/4885CYP2A6 2184/4885MAPT 446/4885 |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3R1, PIK3R5 | CYP1A2 3274/4885CYP2A6 3568/4885MAPT 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.